Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gaush MeditechHKSE:02407 +0.61%67 EV-to-FCF is 6.72 as of Jul. 20, 2026, which is 64% below its 10-year median of 18.80. GuruFocus rates HKSE:02407 with a GF Score™ of 67/100 and a GF Value™ of HK$13.39 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 414 Medical Devices & Instruments companies, Gaush Meditech ranks better than 89.13% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Gaush Meditech's Enterprise Value is HK$819 Mil.
Gaush Meditech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$122 Mil. Therefore, Gaush Meditech's EV-to-FCF for today is 6.72.
The historical rank and industry rank for Gaush Meditech's EV-to-FCF or its related term are showing as below:
HKSE:02407'
s EV-to-FCF Range Over the Past 10 Years
Min: 5.29 Med: 18.8 Max: 51.45
Current: 6.72
During the past 7 years, the highest EV-to-FCF of Gaush Meditech was 51.45. The lowest was 5.29. And the median was 18.80.
HKSE:02407's EV-to-FCF is ranked better than 89.13% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.2
vs HKSE:02407: 6.72
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gaush Meditech's PE Ratio (TTM) for today is calculated as:
Gaush Meditech's share price for today is HK$4.93.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gaush Meditech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.726.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Gaush Meditech EV-to-FCF Related Terms
Gaush Meditech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Gaush Meditech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Gaush Meditech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gaush Meditech EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Gaush Meditech's EV-to-FCF falls into.
Gaush Meditech's current Enterprise Value is HK$819 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gaush Meditech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$122 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gaush Meditech (HKSE:02407) has a EV-to-FCF of 6.72 as of Jul. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Gaush Meditech and its competitors. This is 64% below median its historical median of 18.80. Over the past decade, Gaush Meditech's EV-to-FCF has ranged from 5.29 to 51.45. According to the industry distribution chart, Gaush Meditech ranks #45 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 10.9%.
Is Gaush Meditech's EV-to-FCF too high?
Gaush Meditech's current EV-to-FCF of 6.72 is 64% below median its 10-year median of 18.80. Over the past 10 years, this metric has ranged from a low of 5.29 to a high of 51.45. The Medical Devices & Instruments industry median EV-to-FCF is 23.20. Gaush Meditech's value of 6.72 is 71% below this industry median. Based on the distribution chart, Gaush Meditech ranks #45 out of 414 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Gaush Meditech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gaush Meditech's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gaush Meditech ranks #45 out of 414 companies for EV-to-FCF. This places Gaush Meditech in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 23.20. Gaush Meditech's value of 6.72 is 71% below this benchmark. Historically, Gaush Meditech's own EV-to-FCF has ranged from 5.29 to 51.45 over the past decade. While the company's 10-year median is 18.80 vs. the industry median of 23.20, Gaush Meditech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.20, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gaush Meditech's current EV-to-FCF of 6.72 is 71% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Gaush Meditech and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gaush Meditech's current EV-to-FCF is 6.72, which is 64% below median its own 10-year median of 18.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gaush Meditech stock overvalued right now?
Based on GuruFocus' analysis, Gaush Meditech (HKSE:02407) is currently considered Possible Value Trap. The stock's GF Value™ is HK$13.39, compared to a current price of HK$4.93 — trading 63.2% below its estimated fair value. The current EV-to-FCF is 6.72, which is 64% below median its 10-year median of 18.80 and 71% below the Medical Devices & Instruments industry median of 23.20. Gaush Meditech's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Gaush Meditech (HKSE:02407), the current EV-to-FCF is 6.72 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gaush Meditech (HKSE:02407) Overvalued in 2026?
Based on GuruFocus' analysis, Gaush Meditech stock appears to be undervalued.
The current stock price of HK$4.93 is trading 63.2% below its estimated GF Value™ of HK$13.39.
GuruFocus considers Gaush Meditech to be Possible Value Trap.
Key valuation signals for HKSE:02407:
EV-to-FCF: 6.72 (64% below median its 10-year median of 18.80)
GF Value™: HK$13.39 vs. price of HK$4.93 (63.2% below fair value)
Industry Position: 71% below the Medical Devices & Instruments median (#45 of 414)
No single metric tells the full story. See the HKSE:02407 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gaush Meditech Ltd is a provider of a broad spectrum of manufacture and sale ophthalmic medical devices and provision of technical services. The segments of the company include Proprietary products segment that derives maximum revenue, develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; Technical services segment provides warranty services, maintenance services and other related consumables; and Others segment.
67GF Score
Get the complete analysis for HKSE:02407
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02407 has been successfully added to your 
